Piper Jaffray Starts Sutro Biopharma (STRO) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Wedbush Starts Sutro Biopharma (STRO) at Outperform
October 22, 2018 6:18 AM EDTWedbush analyst David Nierengarten initiates coverage on Sutro Biopharma (NASDAQ: STRO) with a Outperform rating and a price target of $20.00.
For an analyst ratings summary and ratings history on Sutro Biopharma click here. For more ratings news on Sutro Biopharma click here.
Shares of Sutro Biopharma closed at $14.53 yesterday.
... MoreCowen Starts Sutro Biopharma (STRO) at Outperform
October 22, 2018 5:40 AM EDTCowen analyst Boris Peaker initiates coverage on Sutro Biopharma (NASDAQ: STRO) with a Outperform rating.
The analyst comments "Sutro is an early-clinical stage biopharma company that uses its XpressCF platform to generate optimized biologics. This platform generates a homologous pool of ADC... More
JMP Securities Starts Sutro Biopharma (STRO) at Market Outperform
October 22, 2018 4:04 AM EDTJMP Securities analyst Konstantinos Aprilakis initiates coverage on Sutro Biopharma (NASDAQ: STRO) with a Market Outperform rating and a price target of $28.00.
The analyst comments "Sutro is a clinical-stage biopharmaceutical company evolving novel methods to discover and develop protein-based therapies, with the... More
